Aethlon Medical Cmn (AEMD) 6.40 $AEMD Aethlon Medical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aethlon Medical Cmn (AEMD) 6.40 $AEMD

Aethlon Medical Announces Issuance Of Exosome Capture Patent
PR Newswire - Tue Jun 14, 9:28AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent" , related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, including cancer.
AEMD: 6.40 (+0.10)

Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
PR Newswire - Mon Jun 06, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation, which is scheduled to begin at 10:45AM (PT), will review Aethlon Medical's initiatives to combat cancer and infectious disease. Mr. Joyce will also present the discovery of a non-invasive candidate biomarker to diagnose CTE that was made in collaboration with Exosome Sciences, a majority-owned subsidiary of Aethlon Medical. CTE is a neurological disorder associated with exposure to repetitive head impacts, such as those experienced by American football players. At present, CTE can only be definitively diagnosed through post-mortem autopsy. The presentation can be accessed on-line through the following link: http://www.veracast.com/webcasts/bio/internat...220202.cfm
AEMD: 6.40 (+0.10)

Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
PR Newswire - Wed Jun 01, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-investment-forum.html) at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL at 10:20 p.m. Central Time on Friday, June 3, 2016.
AEMD: 6.40 (+0.10)

Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report
Marketwired - Thu May 05, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.
AEMD: 6.40 (+0.10)

Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
PR Newswire - Wed May 04, 8:30AM CDT
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate production of its ELLSA(TM) (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic products.
AEMD: 6.40 (+0.10)

Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
PR Newswire - Mon May 02, 7:45AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.40 (+0.10)

FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce
PR Newswire - Tue Apr 05, 8:00AM CDT
www.FinancialBuzz.com, a leader in the financial media and news space, today announces an exclusive HD video interview with Aethlon Medical, Inc. (NASDAQ: AEMD) Chairman & CEO James Joyce from the floor of the NASDAQ MarketSite.
AEMD: 6.40 (+0.10)

Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
PR Newswire - Thu Mar 31, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient and has consented the enrollment of the next patient. The information was disclosed during an Annual Meeting of Stockholders conducted on March 29, 2016 in San Diego, California. Aethlon had previously disclosed in February 2016, that it had completed the formal training of its new principal investigator, Dr. Ronald Ralph, and had additionally trained two sub-principal investigators to support the advancement of its clinical study.
AEMD: 6.40 (+0.10)

Aethlon Medical, Inc. Reports Annual Meeting Results
PR Newswire - Wed Mar 30, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California.
AEMD: 6.40 (+0.10)

Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
PR Newswire - Wed Mar 09, 5:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30 p.m. ET) on Wednesday, March 16, 2016.
AEMD: 6.40 (+0.10)

Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
PR Newswire - Fri Feb 05, 8:32AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.
AEMD: 6.40 (+0.10)

Aethlon Medical Announces Fiscal 2016 Third Quarter Results
PR Newswire - Thu Feb 04, 3:10PM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fiscal 2016 ended December 31, 2015.
AEMD: 6.40 (+0.10)

Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
PR Newswire - Wed Feb 03, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.
AEMD: 6.40 (+0.10)

Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016.
AEMD: 6.40 (+0.10)

Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
PR Newswire - Fri Jan 29, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.40 (+0.10)

Aethlon Medical's Exosome Sciences To Participate In Clinical Research Study To Diagnose Chronic Traumatic Encephalopathy (CTE)
PR Newswire - Tue Jan 12, 8:00AM CST
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (Nasdaq:AEMD), announced today that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as examining risk factors for CTE. CTE is a disease of the brain often found in athletes, military veterans, and others with a history of repetitive head impacts. At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue.
AEMD: 6.40 (+0.10)

Four Companies Involved in the Diagnosis, Treatment, and Prevention of CTE
ACCESSWIRE - Tue Jan 05, 11:06AM CST
NEW YORK, NY / ACCESSWIRE / January 5, 2016 / BioTechstocks.com - The long term effects of contact sports are something that has long been neglected in the biotech space. Through both lack of quantitative evidence, and lack of financial incentive, very little is known about how and why athletes experience the complications they do later in life. Because of this, diagnosis and treatment is often late in coming and lacking in efficacy when it does. Chronic Traumatic Encephalopathy (CTE) is perhaps the prime example of this. CTE is a degenerative neurological condition that affects athletes across a range of contact sports, and a number of companies have turned their attention to the condition.
PSG: 3.31 (-0.04), AEMD: 6.40 (+0.10), LLY: 83.40 (+1.31)

Equity Market Movement at a Glance - Research on Aethlon Medical, Famous Dave's of America, ID Systems and AgroFresh Solutions
ACCESSWIRE - Fri Dec 04, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Aethlon Medical Inc. (NASDAQ: AEMD), Famous Dave's of America Inc. (NASDAQ: DAVE), ID Systems Inc. (NASDAQ: IDSY) and AgroFresh Solutions Inc. (NASDAQ: AGFS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AEMD: 6.40 (+0.10), IDSY: 4.83 (-0.04), DAVE: 5.90 (-0.07), AGFS: 6.51 (+0.61)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 212

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 238

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 262

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 377

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 192

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading